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Abstract
Background: There has been comparatively little patient information about bronchiectasis, a chronic lung disease
with rising prevalence. Patients want more information, which could improve their understanding and self-
management. A novel information resource meeting identified needs has been co-developed in prior work. We
sought to establish the feasibility of conducting a multi-centre randomised controlled trial to determine effect of
the information resource on understanding, self-management and health outcomes.
Methods/design: We conducted an unblinded, single-centre, randomised controlled feasibility trial with two parallel
groups (1:1 ratio), comparing a novel patient information resource with usual care in adults with bronchiectasis.
Integrated qualitative methods allowed further evaluation of the intervention and trial process. The setting was two
teaching hospitals in North East England. Participants randomised to the intervention group received the information
resource (website and booklet) and instructions on its use. Feasibility outcome measures included willingness to enter
the trial, in addition to recruitment and retention rates. Secondary outcome measures (resource use and satisfaction,
quality of life, unscheduled healthcare presentations, exacerbation frequency, bronchiectasis knowledge and lung
function) were recorded at baseline, 2 weeks and 12 weeks.
Results: Sixty-two participants were randomised (control group = 30; intervention group = 32). Thirty-eight (61%) were
female, and the participants’ median age was 65 years (range 15–81). Median forced expiratory volume in 1 s percent
predicted was 68% (range 10–120). Sixty-two of 124 (50%; 95% CI, 41–59%) of potentially eligible participants approached
were recruited. Sixty (97%) of 62 participants completed the study (control group, 29 of 30 [97%]; 95% CI, 83–99%; 1
unrelated death; intervention group, 31 [97%] of 32; 95% CI, 84–99%; 1 withdrawal). In the intervention group, 27 (84%) of
32 reported using the information provided, and 25 (93%) of 27 of users found it useful, particularly the video content.
Qualitative data analysis revealed acceptability of the trial and intervention. Web analytics recorded over 20,000 page
views during the 16-month study period.
Conclusion: The successful recruitment process, high retention rate and study form completion rates indicate that it
appears feasible to conduct a full trial based on this study design. Worldwide demand for online access to the
information resource was high.
Trial registration: ISRCTN Registry, ISRCTN84229105. Registered on 25 July 2014.
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Background
Bronchiectasis is a chronic lung condition of increasing
worldwide prevalence [1–3]. In the United Kingdom, for
example, prevalence is between 43.4/100,000 in those aged
18–30 and 1239.7/100,000 in those aged 70–79 [1]. In
addition, there is evidence that up to 50% of patients with
chronic obstructive pulmonary disease (COPD) have co-
existent bronchiectasis [4, 5], and as such, case finding of
bronchiectasis is likely to rise further. This rising prevalence
presents a large burden to healthcare service providers [6,
7]. The nature of bronchiectasis, with dilated bronchi lead-
ing to symptoms of breathlessness, chronic productive
cough and intermittent infective exacerbations, presents a
significant burden to patients and their families. Patients
often have recurrent, costly hospital admissions; a poorer
quality of life [8, 9]; and clinically significant fatigue [10, 11].
Current treatments for bronchiectasis include oral, in-
haled or intravenous antibiotics; mucolytics; and physio-
therapy [12]. Timely recognition of symptoms and
improved management of infections could lead to increased
disease stability in bronchiectasis and consequent improve-
ments in health outcomes. Responding appropriately to
symptoms of exacerbation and maintenance treatments
such as chest clearance techniques may prevent deterior-
ation and reduce admissions. Understanding the import-
ance of complex treatment regimens can be challenging for
patients; yet, poor adherence to treatments, such as inhaled
antibiotics, has been shown to worsen outcomes and ex-
acerbation rates [13, 14]. It follows, therefore, that patient
self-care could make a significant impact on healthcare ser-
vice use. To enable patients to self-care, access to accurate
information about their condition is required. Such infor-
mation could empower patients to recognise changes, re-
spond to them and understand how their self-management
could potentially alter their prognosis. The British Thoracic
Society (BTS) guidelines for management of bronchiectasis
recommend education of patients within their management
plan [12]. The BTS provides a brief self-management tool
for patients with bronchiectasis that is available to down-
load. There is relatively little information produced for pa-
tients with bronchiectasis [15].
The evidence that patients with health issues want to be
able to access health information and that it can influence
patient outcomes is long-standing [16–19]. Specifically, in
bronchiectasis, patients report feeling more confident with
managing their condition following information and edu-
cation about their treatment [20], and lack of information
has been highlighted as one of the major barriers to self-
management [21]. In addition, patients with bronchiec-
tasis have described a lack of trustworthy information
available to them beyond that obtained in the clinic and
acknowledge the role of patient information in developing
the skills and confidence to live with and manage their
condition [22, 23].
A prior qualitative study used in-depth interviews to
identify unmet information needs and priorities for an
information resource [24, 25]. Using the themes and
needs identified during analysis of these interviews, a
novel patient information resource has been co-
developed [26]. The content and format of the resource
are based on the findings of the interviews and subse-
quent focus groups with patients and carers to refine the
intervention. A definitive, multi-centre trial using this
novel resource as an intervention would aim to ascertain
if the provision of such patient-focussed information
and education can improve health outcomes in bronchi-
ectasis. The rationale for this feasibility study prior to a
definitive trial was to assess whether the proposed design
for the trial is practicable and would allow the proposed
outcomes to be measured. In addition, the feasibility
study allowed the intervention to be further evaluated
using both quantitative and qualitative approaches.
Objectives
The primary objective of the BRIEF (BRonchiectasis In-
formation and Education Feasibility) study was to deter-
mine the feasibility of conducting a definitive RCT based
on this trial design and establish the need for any refine-
ments to the design or conduct of that trial. The second-
ary objectives of the trial were to assess and further
refine the patient information resources and collect in-
formation on patient preferences. The objectives of a po-
tential future definitive trial would be to evaluate
whether provision of a patient-focussed information and
education resource can improve patient understanding,
self-management and health outcomes in bronchiectasis.
Methods and design: participants, interventions
and outcomes
The BRIEF study was an unblinded, single-centre, ran-
domised controlled feasibility trial with two parallel
groups, comparing a novel patient information resource
with usual care in bronchiectasis. The full study protocol
has previously been published, and no changes were
made to the methods after trial commencement [27].
Study duration for each participant was 12 weeks from
study entry date, with study visits at baseline, week 2
and week 12. Three postal record sheets were also com-
pleted during this time.
The study took place in the Newcastle upon Tyne
Hospitals NHS Foundation Trust, Newcastle upon Tyne,
UK. This consists of two teaching hospital sites: the
Freeman Hospital and the Royal Victoria Infirmary.
Study visits all took place within the Freeman Hospital.
Participants were recruited from either hospital site.
Potential participants were identified by case note re-
view and attendance at outpatient clinics and were given
or sent a letter of invitation to the study and a
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participant information sheet. Written informed consent
was obtained from willing participants. Participants
could withdraw consent at any point with no effect on
usual care. At the end of the study, some participants
were invited to attend a focus group about their experi-
ence. Participants invited to attend the focus group were
sampled purposively. The aim was to form a group that
included participants of differing backgrounds and time
since diagnosis, some from the control and some from
the intervention group, and those who had differing
preferences in terms of format of resource used. Involve-
ment in the focus group, however, was an optional extra,
and as such, a pragmatic approach had to be taken. Par-
ticipants agreeing to take part in the focus group were
invited to bring along their ‘carer’ (e.g., partner or family
member), who was then sent the appropriate informa-
tion sheet to consider whether they would like to take
part. Additional information sheets and consent forms
were produced for ‘carer’ participants.
To be eligible for study inclusion, participants had to
have capacity to provide written informed consent, be
aged 18 years or over, have a clinical and radiological
diagnosis of bronchiectasis, and be able to use the Eng-
lish language. Exclusion criteria included having partici-
pated in the preceding Bronchiectasis Information and
Education study, cognitive impairment, and being unable
to use the English language.
Study intervention
At the baseline visit, participants randomised to the
intervention received the patient information resource:
an overview booklet and website (password required for
website access to www.bronchiectasis.me during study
period). Verbal and written access instructions were
given by appropriate members of the research team. Par-
ticipants had access to the intervention for the duration
of the study. Participants were encouraged to use the re-
source and to allow their families or carers to use them
also. For those who did not wish to or were unable to
access the website, participation using a PDF version of
the information contained within the website was of-
fered. This enabled viewing of all information except the
video clips. Those in the usual care arm did not receive
any additional information but were free to obtain any
information routinely acquired during their usual con-
tacts with their healthcare team or their own informa-
tion seeking. At study completion, those randomised to
the intervention group were allowed continued access to
the resource. Those in the control group were offered
access to the resource following completion of their
study period. Any uptake of the resource following study
completion did not form part of data collection. Any
participant could choose to leave the study at any point
with no effect on usual care.
Outcome measures
The primary outcome measures for the BRIEF study
were those measuring feasibility. These included partici-
pants’ willingness to enter the trial, recruitment rate, ac-
ceptability of study design and completion of required
study forms and visits as per protocol. Secondary out-
come measures included the measures used to evaluate
the information resource and the measures that would
be used within a definitive trial to assess impact of the
intervention upon health-related outcomes. For the pur-
poses of this feasibility study, these measures contrib-
uted to the assessment of completion of study forms by
participants and the resource evaluation process. Mea-
sures included the bronchiectasis knowledge question-
naire (BKQ) (Additional file 3); the Resource Satisfaction
Questionnaire (RSQ) (Additional file 1); and validated
questionnaires such as Quality of Life–Bronchiectasis
(QOL-B), Hospital Anxiety and Depression Scale
(HADS), Fatigue Impact Scale (FIS), and 5-Level Euro-
Qol 5-dimension quality of life scale (EQ-5D-5L). The
number of unscheduled presentations, exacerbation rate
and forced expiratory volume in 1 s (FEV1) could poten-
tially be used in a future full trial as a representation of
the patients’ ability to self-manage their condition.
Health-related quality of life (HRQOL) measures were
also felt to be important to include in a future definitive
trial and were therefore recorded in this study. A recent
review of their use in bronchiectasis has shown that they
have good validity and repeatability. Specifically, QOL-B
and St George’s Respiratory Questionnaire were identi-
fied as having good psychometric properties, and QOL-
B is the only disease-specific HRQOL questionnaire
available for bronchiectasis [28]. Full details are included
in the pre-published study protocol [27].
Outcome measures were recorded at baseline (day 0)
and then at 2 weeks (i.e., shortly after initial viewing of in-
formation in order to facilitate obtaining first opinions)
and 12 weeks after recruitment. This was done during par-
ticipant visits that took less than 1 h each. Visit 2 could be
conducted via telephone. Participants were additionally
asked to complete three postal record sheets (weeks 4, 8
and 12), enabling identification of episodes of change in
symptoms and information resource use.
In addition, at the end of the study, participants (and
their carers) were invited to a focus group to discuss
both the resource itself and the trial process. Whilst the
trial was running, the website use was also monitored
using basic analytics to determine page views, navigation
through the site and attempts at access from those out-
side of the study.
Sample size
Sample size was 70, with a minimum of 30 being rando-
mised to each arm. This was based on previous
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recommendations for good practice in feasibility studies
[29]; no formal power calculations were carried out. Up
to ten ‘carer’ participants were anticipated to be re-
cruited for the end of study focus group, as described
above.
It was estimated that 24 months would be adequate
time to recruit 70 participants to this study, based on a
clinic attendance of approximately 60 per month with
an estimate of 50% of participants approached who were
willing and able to enter. Seventy participants recruited
from among approximately 140 participants approached
would correspond to a 95% CI for the recruitment rate
of 41–59% (an acceptable width of ± 9%). We expected
low attrition rates based on previous work and our prior
experience in this field. There was a 3-month additional
period planned for follow-up of the last recruited partici-
pants and time beyond for the focus group and analysis.
Randomisation
Participants were randomised to intervention or control
groups in a 1:1 ratio, using variable length random per-
muted blocks within strata. Because there was a female
preponderance within the potential study population
and the effect of gender on outcomes was uncertain,
randomisation was stratified by gender. The randomisa-
tion allocation schedule was generated by a statistician
with no other involvement in the study. Randomisation
was performed by the Chief Investigator at site, or by an
individual with delegated authority, using a secure,
password-protected, web-based system administered by
Newcastle Clinical Trials Unit. Blinding was not feasible
for this study for participants or the research team con-
ducting the study visits, owing to the nature of the
intervention.
Statistical methods
Analyses were carried out according to a pre-defined
statistical analysis plan (SAP). Analyses were based on
the intention-to-treat (ITT) principle with analysis
groups based on the groups allocated at randomisation,
with all randomised participants being included in the
analyses. The analyses of the data collected were descrip-
tive, and no formal statistical testing was performed. For
the feasibility objectives 95% CIs have been reported [30,
31]. Validated questionnaires were scored using the
scoring algorithm provided; pre-determined rules for
missing data were followed. For those questionnaires
that were either unvalidated or had no pre-defined rules
for dealing with missing data, missing data points were
treated as such. The extent of missing data was assessed
and reported, and analyses of outcomes at follow-up
time points were carried out on a complete-case basis.
Rates were calculated as defined. At baseline and by
intervention group, the distribution of all numerical
variables was examined graphically and summarised by
the median and range. Baseline categorical variables were
tabulated, and percentages reported. The changes from
baseline to 2 weeks and baseline to 12 weeks, for all vali-
dated health-related and quality of life outcomes, have
been reported as means and SDs, the purpose being to in-
form the design of any future definitive trials (Table 3).
No inferential analyses have been performed, because the
study was not powered to do so. Not all the analyses pro-
posed in the published protocol paper [27] were included
in the SAP. For the secondary outcomes, CIs for the esti-
mated difference in the change from baseline between
intervention groups have not been reported. Statistical
analyses were performed using IBM SPSS Statistics ver-
sion 22.0 software (IBM Corp., Armonk, NY, USA).
The focus group conducted at the end of the study ex-
plored the experiences of participants and their carers.
Topics covered both their views on the resource and
their views on the trial itself. A thematic analysis ap-
proach was taken [32–34]. The group discussion was
audio-recorded and transcribed verbatim, and transcripts
were used to read, re-read and confirm issues identified
during the focus group. Feedback themes were identi-
fied, summarised and reported.
Results
Participant recruitment and flow
Overall, 62 participants were randomised. Recruitment
took place over a 16-month period (10th June 2014
through 23rd September 2015), with a participant recruit-
ment rate of 3.9/month. Of the 124 potentially eligible
participants approached, 44 declined participation (35%),
15 were uncontactable after attempts to re-contact follow-
ing receipt of the participant information sheet (12%), and
3 were ineligible (2%). Overall 62 of 124 (50%; 95% CI,
41–59%) of those approached were willing and eligible to
enter the study. There were two serious adverse events
unrelated to the study, including one death. Two with-
drawals from the study were made (one change in per-
sonal circumstance, one death). The Consolidated
Standards of Reporting Trials (CONSORT) diagram fur-
ther details participant flow through the study (Fig. 1).
The ITT analysis set included all randomised participants
(N = 62). The study ‘completers’ analysis set included all
randomised participants, retaining participants in their
randomised allocation groups, who attended their final
study visit at 12 weeks post-randomisation (n = 60) and
was used for analyses of change data.
Baseline characteristics
Demographic and clinical baseline characteristics were
compared across treatment groups descriptively. For these
baseline study entry characteristics, data for all participants
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were included (ITT analysis set; N = 62). To describe the
population at baseline, features characterising individuals
(e.g., age, gender), the nature of their disease (e.g., lung
function, severity scores {Bronchiectasis Severity Index
[35]}, time since diagnosis, microbiology), and information
seeking were recorded (Table 1). Overall more women were
recruited than men, which had been anticipated in keeping
with the patient demographic. There were approximately
equivalent male-to-female ratios in each group. Median age
was 65 in both groups. Median FEV1 percent predicted
values were 75% in the intervention group and 67% in the
control group. Most characteristics at baseline were ap-
proximately balanced between randomised groups; descrip-
tively, there were more participants in the intervention
group who had had bronchiectasis for more than 10 years
(17 of 32 [53%] versus 9 of 30 [30%]). The numbers of those
who had a relatively new diagnosis (< 1 year) were more
even (6 of 30 [20%] in the control group versus 6 of 32
[18%] in the intervention group). The number of patients
attending a specialist bronchiectasis clinic formed the ma-
jority in both groups.
Feasibility outcome measures
Sixty-two of 124 (50%; 95% CI, 41–59%) potentially eli-
gible participants were consented and entered the study.
A projected participant recruitment rate of two or three
per month was surpassed, with an actual recruitment
rate of 3.9/month.
Study completion rates were recorded as a measure of
acceptability of the trial design to participants, which
formed part of the assessment of feasibility. Two partici-
pants did not complete the study (one death in the control
arm; one lost to follow-up in the intervention arm). There
were therefore 60 (97%) of 62 participants in the ‘com-
pleters’ analysis set (Table 2). In the study completers
group, all participants completed the three required study
visits as per protocol.
For the purposes of determining feasibility, the comple-
tion rates of all questionnaires and lung function tests were
examined. Summaries of complete cases for both validated
and unvalidated questionnaires and lung function were tab-
ulated (Additional file 4). The majority of questionnaires
had 100% completion rate. QOL-B treatment burden does
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram
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Table 1 Baseline characteristics by allocation group (intention-to-treat analysis set)
Control group
(n = 30)
Intervention group
(n = 32)
Total
(N = 62)
Gender
Female 18 (60%) 20 (62.5%) 38 (61%)
Male 12 (40%) 12 (37.5%) 24 (39%)
Age (years)
Median (range) 65 (34–81) 65 (18–81) 65 (18–81)
FEV1 (% predicted)
Median (range) 75 (21–120) 67 (10–110) 68 (10–120)
BSI scorea
Median (range) 6 (2–15) 7 (2–14) 6 (2–15)
BSI severity group
Mild (score 0–4) 9 (30%) 13 (41%) 22 (35%)
Moderate (score 5–8) 14 (47%) 13 (41%) 27 (44%)
Severe (score > 8) 7 (23%) 6 (19%) 13 (21%)
Time since diagnosis (years)
Median (range) 6 (0.5–70) 15 (0.25–70) 10 (0.25–70)
> 10 9 (30%) 17 (53%) 26 (42%)
> 5≤ 10 5 (17%) 2 (6%) 7 (11%)
> 1≤ 5 10 (33%) 6 (19%) 16 (26%)
> 6months ≤ 1 year 5 (17%) 3 (9%) 8 (13%)
≤ 6 months 1 (3%) 3 (9%) 4 (6%)
Bronchiectasis aetiology
Idiopathic
Post-infection 12 (40%) 10 (31%) 22 (35%)
Secondary to chronic asthma/COPD 6 (20%) 11 (34%) 17 (27%)
Immune deficiency associated 7 (23%) 5 (16%) 12 (19%)
Otherb 2 (7%)
3 (10%)
1 (3%)
5 (16%)
3 (5%)
8 (13%)
Exacerbations per year
< 3 13 (43%) 10 (31%) 23 (37%)
≥ 3 17 (57%) 22 (69%) 39 (63%)
Use of home intravenous antibiotics
Y 8 (27%) 15 (47%) 23 (37%)
N 22 (73%) 17 (53%) 39 (63%)
Clinic attended
Specialist 28 (93%) 30 (94%) 58 (94%)
General 2 (7%) 2 (6%) 4 (6%)
Prior bronchiectasis hospital admissions
Y 16 (53%) 25 (78%) 41 (66%)
N 14 (47%) 7 (22%) 21 (34%)
Sputum microbiology
Pseudomonas aeruginosa 8 (27%) 9 (28%) 17 (27%)
Otherc 8 (27%) 11 (34%) 19 (31%)
Not colonised 13 (43%) 11 (34%) 24 (39%)
No samples 1 (3%) 1 (3%) 2 (3%)
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not generate a score if the participant is receiving no
treatments, hence an apparent lower completion rate;
this reflects the scoring system rather than a reduced
completion rate.
Health-related and quality of life measures
Numbers of complete cases and descriptive analysis of
baseline and change data for all validated questionnaires
and lung function tests are compiled in Table 3. Baseline
means were similar in both groups for the majority of mea-
sures, with the exception of a descriptively higher mean
FIS score and a higher mean FEV1 percent predicted in the
control group. Within both the control group and the
intervention group, the mean changes from baseline to 12
weeks are mostly considered small, clinically, with their as-
sociated SDs indicating relatively large variation in the
change between participants. Descriptively, there were
mean changes in outcomes in both the direction of im-
provement and of worsening in both the control group
and the intervention group. No further statistical analyses
were carried out, in keeping with the pre-defined SAP.
Bronchiectasis knowledge questionnaire
The BKQ is an unvalidated questionnaire consisting of 26
statements detailing understanding of bronchiectasis and
its management. Fifteen of the statements ask for a self-
grading of understanding using a Likert scale, and 11 ask
for a true-or-false response (Additional file 3). A summary
of all question responses is tabulated and presented as an
appendix due to the volume of data (Additional file 5).
BKQ completion rates were high. Descriptively, a greater
percentage of participants reported understanding aspects
of their condition ‘very well’ by visit 3 for all 15 of the
Likert scale statements in the intervention group and for 8
of 15 statements in the control group. Because the BKQ is
not validated and in keeping with the pre-defined SAP,
the results of the responses to this questionnaire are only
reported descriptively. No statistical significance has been
attached to this apparent increase in understanding
amongst the group receiving the educational intervention
in this feasibility study.
Resource evaluation
The RSQ was administered only to participants in the
intervention group. Twenty-seven (84%) of 32 reported
using the information provided, 25 (93%) of 27 of users
found it useful, particularly the video content. More than
80% thought that the information was easy to use, covered
the topics they wanted, and that the right amount was
given. By visit 3, 18 (64%) of 28 felt that they were more
able to manage their bronchiectasis (Table 4). Feedback
Table 1 Baseline characteristics by allocation group (intention-to-treat analysis set) (Continued)
Control group
(n = 30)
Intervention group
(n = 32)
Total
(N = 62)
Drug treatments
Azithromycin 10 (33%) 18 (56%) 28 (45%)
Nebulised antibiotics 6 (20%) 3 (9%) 9 (15%)
Devices used to access Internet/resource
Mobile 2 (7%) 8 (25%) 10 (16%)
Tablet 13 (43%) 10 (31%) 23 (72%)
PC/laptop 28 (93%) 28 (88%) 56 (90%)
No access 0 1 (3%) 1 (2%)
Previous bronchiectasis information seeking
None 9 (30%) 5 (16%) 14 (23%)
Paper 9 (30%) 14 (44%) 23 (37%)
Online 14 (47%) 16 (50%) 30 (48%)
In person 4 (13%) 3 (9%) 7 (11%)
Abbreviations: BSI Bronchiectasis Severity Index, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, PC personal computer
aNewcastle Bronchiectasis Severity Index, computed tomographic scoring not included
bPink disease, rheumatoid arthritis, Marfan syndrome, connective tissue disease, granulomatosis with polyangiitis
cHaemophilus influenzae, Klebsiella spp., Staphylococcus aureus, Serratia marcescens, Moraxella catarrhalis, Escherichia coli
Table 2 Study completion rates
Outcome
measure
Total (N = 62)
Control group (n = 30) Intervention group (n = 32)
Study completers 29/30 (97%; 95% CI, 83–99%) 31/32 (97%; 95% CI, 84–99%)
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about the resource from the RSQ is compiled in Tables 5
and 6.
Focus group and web analytics
In total, 11 people attended the end-of-study focus group,
comprising 8 patient participants and 3 carers, male and
female, from both the control and intervention groups.
One participant had no Internet access and had elected to
enter the study with the PDF version of the site. Partici-
pants had a range of ages and times since diagnosis. Par-
ticipants reported not having found the trial
burdensome. Regarding the content of the informa-
tion resource, participants commented that they had
learnt new things and thought it was a good resource
Table 3 Summary of baseline and change data for lung function and validated questionnaires
No. Control group (n = 29) No. Intervention group (n = 31)
Baseline
mean (SD)
Mean changea,
baseline to
2 weeks (SD)
Mean change,
baseline to
12 weeks (SD)
Baseline
mean (SD)
Mean change,
baseline to
2 weeks (SD)
Mean change,
baseline to
12 weeks (SD)
EQ-5D-5Lb
Index value 29 0.75 (0.24) 0.01 (0.17) -0.5 (0.19) 31 0.70 (0.23) 0.06 (0.13) 2.11 (11.7)
VAS 29 68.6 (18.5) −1.55 (13.0) 0.48 (16.2) 31 65.4 (18.0) 5.97 (12.0) −3.0 (16.7)
SGRQc
Symptoms 29 57.6 (23.4) 0.25 (15.0) 30 65.9 (21.3) −7.89 (25.7)
Activity 27 56.3 (23.5) –4.85 (13.4) 31 56.1 (28.3) −4.79 (14.8)
Impacts 29 33.6 (21.5) 0.02 (11.3) 31 32.9 (17.2) −3.06 (13.0)
Total 27 46.1 (19.9) −1.53 (8.3) 30 44.9 (19.1) −2.62 (9.46)
QOL-Bd
Physical 29 48.1 (32.3) 2.30 (17.8) -3.85 (16.7) 30 51.6 (35.1) 3.11 (16.2) -4.94 (25.2)
Role 29 63.5 (29.3) 0.23 (13.6) 1.32 (17.6) 30 64.9 (25.8) 5.33 (18.7) 2.22 (17.8)
Vitality 29 44.1 (24.0) –1.53 (18.5) 0.38 (16.9) 30 43.7 (22.4) 4.44 (18.4) -0.74 (21.0)
Emotion 29 84.0 (17) 1.05 (14.9) -2.1 (13.0) 30 85.0 (18.6) 4.44 (15.3) 2.22 (10.2)
QOL-B
Social 29 59.7 (31.2) -0.077 (22.1) 2.97 (14.7) 30 58.1 (22.8) 5.37 (17.2) 3.14 (19.0)
Treatment burdene 21 71.2 (22.7) –1.06 (16.8) 0.53 (14.7) 22 71.7 (21.6) 2.02 (14.8) 1.01 (14.1)
Health 29 45.0 (25.3) 1.25 (18.2) -0.10 (13.0) 30 44.0 (24.3) 7.04 (15.8) 3.06 (18.4)
Respiration 28 60.6 (23.7) 3.97 (17.3) 3.6 (16.3) 30 54.3 (22.8) 9.7 (14.6) 6.3 (16.8)
HADSf
A 29 5.69 (3.87) –0.14 (2.86) –0.31 (3.11) 31 5.87 (4.01) −1.32 (2.4) 0.44 (6.6)
D 29 4.52 (3.61) 0.00 (2.38) 0.14 (1.76) 31 3.81 (2.33) −0.10 (1.7) 2.12 (13.2)
FISg
Cognitive 29 8.52 (9.44) 2.07 (7.2) 31 7.55 (5.84) 1.26 (5.7)
Physical 29 15.52 (12.3) −1.69 (5.6) 31 12.9 (8.18) 0.39 (6.9)
Social 29 21.79 (21.95) −0.59 (8.8) 31 15.7 (13.4) 2.72 (12.9)
Total 29 45.8 (42.5) −0.21 (18.3) 31 36.2 (26.0) 2.70 (19.7)
FEV1 (% predicted) 28 72.6 (26.7) 3.78 (8.61) 30 63.7 (23.8) −0.78 (10.1)
FEV1 (L) 28 1.82 (0.73) 0.08 (0.23) 30 1.64 (0.75) 0.23 (1.15)
Abbreviations: EQ-5D-5L 5-level EuroQol 5-dimension quality of life scale, FEV1 forced expiratory volume in 1 s, FIS Fatigue Impact Scale, HADS Hospital Anxiety and
Depression Scale, QOL-B Quality of Life–Bronchiectasis, SGRQ St George’s Respiratory Questionnaire, VAS visual analogue scale
aA negative change indicates a numerical fall, on average, from baseline to 12 weeks
bEuroQol-5D-5L: self-reported health status (VAS range, 0–100%)
cSt George’s Respiratory Questionnaire: scores are a percentage of overall impairment; 100 represents worst possible health status, and 0 indicates best possible
health status
dQuality of Life – Bronchiectasis: scored 0–100, higher score = better quality of life
eTreatment burden is not scored if participant is receiving no treatment, hence apparent lower n value
fHospital Anxiety and Depression Scale: anxiety 0–21, depression 0–21; scores 11+ are significant
gFatigue Impact Scale: cognitive, 0–40; physical, 0–40; social, 0–80; total, 0–160. Higher score = bigger impact of fatigue
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for learning about how to find more information on
bronchiectasis. The website received favourable re-
views, in particular in comparison to other available
resources, as this carer stated:
‘To answer your question about the website, be-
cause I’ve looked at other things, I think it’s clear,
concise.… It’s easier to understand.… The thing
that’s good about it you’ve got a carer’s perspective,
you’ve got patient perspective, consultant and so
on.’ Arthur, 71yrs
They qualified their opinion by explaining that they had
seen other resources and explained that they liked the fact
that this information resource is both patient- and carer-
oriented. Further positive features of the website that were
identified were the videos, that you cannot mislay it like
you could a leaflet, and that it is easier to update.
Basic web analytics were performed using Google Ana-
lytics. Over the duration of the study, there were 7553
sessions of 6456 users, with over 20,000 attempted page
views. The large number of attempted page views was
due to the fact that the website could be found using
search engines but could not be accessed beyond the
home page without a password that was a unique code
given to each participant in the intervention group. The
‘bounce’ rate (number of users leaving the site without
looking beyond the entry page) therefore was high,
because only permitted users could access the site.
Pages about diet and lifestyle advice were the most
popular, with ‘learning about prognosis’; ‘getting a
diagnosis’; ‘Why have I got bronchiectasis?’; ‘What
symptoms I might get?’; and ‘Who might I need to
see?’ also being very popular. Although these data do
not accurately describe the use of the site by individ-
ual participants, identifying topics of greatest interest
to those searching for information about bronchiec-
tasis is of value.
Discussion
The BRIEF study demonstrated it was feasible to recruit
patients into a trial concerning patient education in
bronchiectasis. Pre-defined feasibility outcomes were
met. Willingness to enter the trial was within predicted
numbers, and the recruitment rate was higher than ex-
pected. Study design was acceptable as judged by study
completion rates, qualitative feedback in the end-of-
study focus group, and the completion of study forms as
per protocol. Many of the questionnaires used achieved
100% completion rates. The postal questionnaire com-
pletion rates were in excess of published average postal
Table 4 Resource Satisfaction Questionnaire review of information overall
No. completing questionnaire (n = 31) Agree, no. (%) Neutral, no. (%) Disagree, no. (%)
1. I found the information useful.
V2 27 25 (93) 1 (4) 1 (4)
V3 28 26 (93) 1 (4) 1 (4)
2. My knowledge about my condition has improved.
V2 27 22 (81) 4 (15) 1 (4)
V3 28 18 (64) 8 (29) 2 (7)
3. I feel more able to manage my condition.
V2 27 13 (48) 12 (44) 2 (7)
V3 28 18 (64) 8 (29) 2 (7)
4. The information provided was easy to understand.
V2 27 26 (96) 0 1 (4)
V3 28 25 (89) 1 (4) 2 (7)
5. The right amount of information was given.
V2 27 24 (89) 2 (7) 1 (4)
V3 28 23 (82) 4 (14) 1 (4)
6. The things I wanted to know about were covered.
V2 27 25 (93) 2 (7) 0
V3 28 24 (86) 2 (7) 2 (7)
7. My partner/family member/friend used the information.
V2 27 11 (41) 3 (11) 13 (48)
V3 27 15 (56) 4 (15) 8 (30)
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questionnaire return rates of 65% [36]. Data quality was
exemplary, with very few missing data or errors.
On the basis of these findings, it can be concluded that
this study was feasible to conduct. This is key when design-
ing a definitive, larger, multicentre trial based on this study
design; yet, there are additional points to consider when
moving from pilot to definitive studies [37, 38]. Specifically
for the BRIEF study, points to consider for further planning
would include the ability to recruit from different centres,
planning required follow-up time, retention rates with a
longer study follow-up time, and changes to study design to
improve chances of recruiting adequate numbers. Planning
a definitive trial with an adaptive design would allow for re-
assessment of required sample size during recruitment and
data collection. For outcomes such as frequency of exacer-
bations, a much longer follow-up period of at least 1 year
would be required, given the likely number of exacerbations
per year and the seasonal variation that can occur [39].
Based on the findings of the BRIEF study, this study design
is acceptable and feasible to conduct and could be easily
adapted to plan a future definitive trial.
There were some apparent differences (descriptively)
at baseline between the groups, such as time since diag-
nosis. Time since diagnosis may influence the type of in-
formation needs a person may have. During prior
interviews, however, it was apparent that although some
information needs do change over time, many un-
answered questions were common to those who had
both new and long-standing diagnoses [26]. To avoid
this being a potential confounder, stratification by time
since diagnosis could be considered when planning a full
trial. With larger numbers in a definitive trial, however,
it would be anticipated that the balance between arms
for potential confounders would even out.
Feedback in the RSQ identified that participants used
the resource (84%), and 93% of users found it useful.
Users highlighted their like of the video clips within the
website, particularly those depicting other patients’ stor-
ies. Website access or ‘logins’ had been problematic for
some. It was unclear whether this was an issue with the
website or the users’ devices, but this is clearly an area
for improvement. By using the data obtained via website
analysis, numbers accessing the site and most popular
webpages were identified. Demand for access to the site
was shown to be high worldwide, confirming patients
want to be able to access credible bronchiectasis infor-
mation resources. This web analysis facilitated obtaining
feedback about the resource and re-confirming prior
qualitative findings. This is the first trial of a bronchiec-
tasis information resource that has been based on quali-
tative exploration and understanding of users’ needs and
experiences. Patients and carers were involved in the
study and intervention design from the outset, in
addition to an independent user representative. A study
Table 5 Resource Satisfaction Questionnaire free-text positive
comments
Positive comments
Regarding the
use of video
Enjoyed watching the video of patients
Video clips helpful
Liked patient video clips
Found videos comforting
Found videos of patients doing nebulisers
useful
The videos were good
Confirmation of own self-management
technique helpful also seeing other
patients, same problems helpful
Regarding the
website
I will use the website in future especially
as I will be out of the country for 2 months.
Website excellent
General overall views Quite happy with resources provided
Everything was clear and easy to understand
Thought good and clear, language good,
easy to understand
Well balanced
Well done
I can never have enough information.
Regarding use
by family
My youngest son has a better understanding
of bronchiectasis.
Table 6 Resource Satisfaction Questionnaire free-text
suggestions for improvement
Problems or suggestions
Regarding the
use of video
Would like more case studies
A patient sharing how to use the nebuliser
would be more helpful than a technician
showing how it works.
More patient stories
Regarding the website Problems getting on to Internet site
Unable to access website
When scrolling down things disappeared
but did come back.
Login email + password could be clearer
Patient unable to access website due to
invalid password
Advice sought from research staff
Could not access web on my computer
Could not get on website: password
General overall views I have not used the information provided
due to hospital stay and work commitments.
I find that now the information has stopped
for me. I.e., there is nothing new to read about.
Regarding use
by family
Family members not interested, just want
me well, quite embarrassed about emotion
and keep quiet about my condition.
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protocol was produced in keeping with the Medical Re-
search Council guidelines for evaluating complex inter-
ventions [40], and this was published and made openly
accessible [27]. Findings have been reported in keeping
with the CONSORT guidelines [31, 41], and a pre-
defined SAP was used when analysing data. As with any
study, however, there are some limitations to consider.
The first limitation concerns blinding. This was a
feasibility study, with limited funding and a sample size
of 62. Due to the nature of the intervention, participants
could not be blinded to whether they were receiving the
resource to use whilst in the study. As the research staff
conducting study visits needed to provide access details
and support to those within the intervention group, they
too were unblinded in order to ensure data were ana-
lysed without bias and not influenced during analysis,
and a pre-defined SAP was written with advice from a
statistician prior to data analysis [27].
At the time of study commencement, there was no gold
standard for objectively measuring what constitutes an ex-
acerbation in bronchiectasis. More recently, however, a
consensus has been reported for the definition to be used
in clinical research [42]. A future study would use this def-
inition. The BRIEF study used participant recollection and
case note review to identify exacerbations. Patient re-
viewers of the initial study design raised concerns about
the potential burden of a daily symptom diary. Hence, we
opted to ask participants to record such details on a
monthly basis. In a definitive trial of this intervention,
however, improvements in self-management and conse-
quently disease stability would need to be assessed. When
adapting this study design for a future trial, a protocol def-
inition of an exacerbation and more rigorous reporting of
events would be preferable. This could include, for ex-
ample, electronic symptom diaries.
Although participants were recruited from all respiratory
clinics within the trust, at two sites, 58 (94%) of 62 were re-
cruited from the specialist bronchiectasis clinic. The aim
was to have a participant group who had different clinical
experiences and differing information provision. Those
attending a specialist clinic would potentially have access to
a level of information beyond that expected in a general re-
spiratory clinic. This is not necessarily the case. Arguably,
however, which clinic the participant attended, or prior in-
formation provision, could be considered as a stratification
variable during randomisation for a definitive trial if
thought to be a potential confounding factor. Other related
factors that could potentially influence outcomes or the im-
pact of an educational intervention could also be consid-
ered as stratification variables for a full trial. Examples
could include time since diagnosis (which could influence
the nature of information required and prior opportunities
to access information), access to the Internet (which could
affect formats of resource able to fully engage with) and
education or health literacy levels (which could influence
both types of resources required and ability to engage with
and understand them).
Accessing additional information resources during the
BRIEF study was not restricted. The significant differ-
ence in information provision for the two groups within
the trial was the novel information resource. The ability
to monitor additional seeking or provision of informa-
tion is limited and really has to be accepted as a variable
which is not practicably controllable and reflects ‘usual’
patient practices. At study conclusion, all those who had
taken part in the study (including those in the control
group) were given access to the resource indefinitely.
Numbers of courses of antibiotics would be important
information to collect within a definitive trial, though it
would be difficult to use as a primary outcome measure.
Because the intervention would aim to improve partici-
pants’ recognition and management of exacerbations,
this could lead to an increase in number of antibiotic
courses taken (if a participant had previously been
under-recognising treatment requirements); yet, for
others, it may lead to a reduction (if they had previously
been reacting to ‘normal’ variations in symptoms un-
necessarily). Measuring change in number of courses of
antibiotics therefore would be difficult to interpret with
meaning. It is likely that exacerbation rate, along with a
primary outcome measure of unscheduled healthcare
visits (representing unpredicted and unmanaged exacer-
bations), would be the most accurate measure of im-
provements in self-management and health outcomes.
This would be in conjunction with assessing knowledge
and understanding of bronchiectasis. In order to more
accurately report this, further work would need to be
done to improve on and validate the knowledge ques-
tionnaires used within the BRIEF study.
Despite the limitations of the BRIEF study, the design
had a number of strengths, and it was conducted suc-
cessfully. The majority of the highlighted limitations are
factors to consider for a definitive trial based on this
feasibility study. Resource evaluation and qualitative data
added to the usefulness of this study by informing re-
finements to both the resource and trial design. For this
feasibility study design to be adapted for a future defini-
tive trial, changes would need to be made as discussed,
and an initial sample size calculated using the data
presented.
Conclusions
The BRIEF study was feasible to conduct and indicates
that a future, multicentre study based on this trial design
to evaluate the impact of this resource on patient under-
standing, self-management, health outcomes and health
service use would be feasible to conduct.
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